Clinical Trial Update: Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating valganciclovir for reducing CMV-related deafness in congenital CMV infection; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Cytomegalovirus Infection

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Congenital Cytomegalovirus (CMV) | Phase 2, Phase 3 | Status: TERMINATED